PS2 Antibody

What is PS2 antibody and what specific targets does it recognize?

PS2 antibody (also referred to as TFF1/pS2 antibody) is an immunoglobulin that specifically recognizes the TFF1/pS2 protein, a trefoil factor with a molecular weight of approximately 6.5 kDa . In particular, monoclonal variants like PS2GE2 target a synthetic peptide derived from the C-terminus of human TFF1/pS2 protein . Additionally, there are specific anti-pS2 antibodies that recognize phosphorylated serine residues (pSer2) in the C-terminal domain (CTD) of RNA polymerase II, which plays a critical role in transcriptional regulation . These antibodies exhibit varying degrees of specificity and affinity depending on the phosphorylation pattern of their target peptides, making them valuable tools for investigating post-translational modifications in research settings.

What applications are PS2 antibodies optimized for in research settings?

PS2 antibodies have been validated for multiple research applications, enabling comprehensive analysis of TFF1/pS2 expression and phosphorylation patterns. The primary validated applications include:

• Flow Cytometry (recommended concentration: 0.5-1.0 μg/10^6 cells)

• Immunocytochemistry/Immunofluorescence (0.5-1 μg/ml)

• Immunohistochemistry (dilution range: 1:10-1:500)

• Immunohistochemistry-Paraffin (0.5-1 μg/ml)

• Immunoprecipitation (dilution range: 1:10-1:500)

• Western Blot (dilution range: 1:100-1:2000)

• CyTOF-ready applications

In particular, anti-pS2 antibodies have proven especially valuable in ChIP (Chromatin Immunoprecipitation), Western blotting, immunofluorescence studies, and immunostaining techniques that require precise detection of phosphorylation states . Researchers have successfully employed these antibodies to gain insights into the CTD code and its role in transcriptional regulation and epigenetic processes.

How do different anti-pS2 antibodies compare in terms of specificity and sensitivity?

Comparative analysis of three recombinant rabbit-generated IgG phospho-specific anti-pS2 antibodies (E1Z3G from Cell Signaling Technology, EPR18855 from Abcam, and 2G1 from Thermo Fisher/Invitrogen) revealed significant differences in their binding characteristics . These antibodies demonstrate distinct positional selectivity and varying affinities for pSer2-containing peptides:

These differences highlight the importance of selecting the appropriate antibody based on the specific experimental context and target epitope location .

What are the critical factors to consider when designing experiments using PS2 antibodies?

When designing experiments with PS2 antibodies, researchers should consider several critical factors to ensure reliable and reproducible results:

• Phosphorylation status: The recognition of pSer2 by anti-pS2 antibodies can be significantly affected by the phosphorylation of neighboring amino acids. Some phosphorylations can prevent antibody binding while others can enhance recognition .

• Peptide length and structure: The length of the phosphopeptides influences antibody binding and specificity. Studies with peptides containing 6 and 12 heptad repeats have shown that positional effects and multivalent interactions differ significantly from studies using shorter diheptapeptides .

• Position of the epitope: The position of pSer2 within the peptide sequence dramatically affects antibody binding. For example, E1Z3G shows higher affinity for peptides with phosphorylation in central positions, while EPR18855 and 2G1 exhibit enhanced binding to peptides with C-terminal phosphorylation .

• Neighboring modifications: The presence of other post-translational modifications can significantly influence antibody recognition. For instance, phosphorylation at Thr4 in the +2 position relative to pSer2 blocks recognition by anti-pS2 antibodies, while phosphorylation at Ser7 in the -2 position enhances binding .

• Antibody selection: Different anti-pS2 antibodies exhibit varying specificities and binding characteristics, making antibody selection a critical experimental parameter that should be guided by the specific research question and target context .

How should researchers optimize immunohistochemistry protocols when using PS2 antibodies?

Optimizing immunohistochemistry protocols for PS2 antibodies requires attention to several key parameters:

• Antibody dilution optimization: Begin with the recommended dilution range (1:10-1:500 for immunohistochemistry applications) and perform titration experiments to determine the optimal concentration that maximizes specific signal while minimizing background .

• Antigen retrieval considerations: Staining of formalin-fixed tissues requires appropriate antigen retrieval techniques to expose the epitope. Heat-induced epitope retrieval methods are typically recommended, but the specific buffer and conditions may need optimization based on the particular PS2 antibody being used .

• Blocking optimization: Sufficient blocking is crucial to minimize non-specific binding. BSA-free formulations of PS2 antibody (such as the PS2GE2 clone) may require adjusted blocking protocols compared to standard antibody preparations .

• Incubation conditions: Optimize both primary and secondary antibody incubation times and temperatures to achieve the best signal-to-noise ratio. Overnight incubation at 4°C often yields better results for primary antibody compared to shorter incubations at room temperature.

• Detection system selection: Choose an appropriate detection system based on the required sensitivity and the specific application. Amplification systems may be necessary for detecting low-abundance targets.

• Validation controls: Always include positive controls (tissues known to express TFF1/pS2), negative controls (tissues without TFF1/pS2 expression), and technical controls (primary antibody omission) to validate staining specificity.

What methods can be used to validate PS2 antibody specificity in experimental systems?

Validating PS2 antibody specificity is essential for ensuring reliable experimental results. Several complementary approaches can be employed:

• Competitive binding assays: Test antibody specificity by performing competition experiments with synthetic peptides. For example, unphosphorylated peptides should not compete against immobilized phosphopeptides for anti-pS2 antibody binding, while phosphorylated peptides at the specific target site should efficiently compete .

• Cross-reactivity assessment: Evaluate potential cross-reactivity with other phosphorylation sites by testing antibody binding to peptides containing phosphorylation at different positions. For instance, hexaphosphorylated CTD peptides containing pThr4, pSer5, or pSer7 residues should not be recognized by specific anti-pS2 antibodies .

• Knockout/knockdown validation: Use genetic approaches to deplete the target protein (TFF1/pS2) or modify the phosphorylation site, then confirm loss of antibody signal.

• Multiple antibody comparison: Compare the staining patterns obtained with different PS2 antibody clones targeting the same epitope. Consistent results across different antibodies suggest higher specificity.

• Mass spectrometry validation: Use mass spectrometry to confirm the presence and phosphorylation status of the target protein in immunoprecipitated samples.

• Phosphatase treatment controls: Treat samples with phosphatases to remove phosphorylation modifications and confirm the loss of antibody binding, validating phospho-specificity.

How does multiphosphorylation affect PS2 antibody recognition and experimental interpretation?

Multiphosphorylation has complex effects on PS2 antibody recognition that researchers must consider when designing experiments and interpreting results:

• Positional effects of bystander phosphorylation: Phosphorylation of amino acids near the target pSer2 can either enhance or inhibit antibody binding. For example, phosphorylation at Thr4 in the +2-position blocks recognition by anti-pS2 antibodies, while pSer7 in the -2-position enhances binding . This positional effect is antibody-specific and can significantly impact experimental outcomes.

• Hierarchical influence of competing modifications: When multiple phosphorylations are present, their effects on antibody binding follow a hierarchy. Research has shown that the negative effect of phosphorylation at the +2 and +3 positions of pSer2 overrules the positive effect provided by phosphorylation in the -2 position .

• Multivalency considerations: Contrary to expectations, multivalent binding (multiple pSer2 sites) does not significantly enhance antibody binding for most anti-pS2 antibodies. For example, presenting pSer2 residues at distances of 1-5 heptads enhanced antibody affinity to a negligible extent (<2-fold) . This is likely due to the high flexibility of the CTD scaffold that prevents optimal positioning for multivalent interactions.

• Antibody-specific responses to clustered phosphorylation: Different antibodies respond differently to clustered phosphorylation patterns. The E1Z3G antibody showed a 5-fold enhancement in affinity when binding to hexaphosphopeptides or when pSer2 was accompanied by adjacent pSer2 modifications. In contrast, EPR18855 and 2G1 antibodies did not demonstrate enhanced binding to clustered pSer2 presentations .

What strategies can enhance the sensitivity of PS2 antibody-based detection in complex biological samples?

Enhancing PS2 antibody detection sensitivity in complex samples requires sophisticated technical approaches:

• Signal amplification systems: Utilize tyramide signal amplification (TSA) or other enzymatic amplification methods to boost signal detection, especially for low-abundance targets or when working with tissue microarrays.

• Optimized peptide design for calibration: Employ synthetic multiphosphorylated CTD peptides in high purity without HPLC purification through advanced synthesis strategies like native chemical ligation . These well-characterized peptides serve as excellent standards for calibrating detection sensitivity.

• Multiplexed detection approaches: Combine PS2 antibody detection with other markers through multiplexed immunofluorescence or mass cytometry (CyTOF) to enhance contextual information and improve signal discrimination from background .

• Pre-enrichment strategies: Use affinity purification or subcellular fractionation to concentrate the target protein before antibody detection, enhancing the signal-to-noise ratio.

• Consideration of phosphorylation context: Account for the impact of neighboring phosphorylations on antibody recognition. Strategic selection of antibodies that are either enhanced or unaffected by specific neighboring modifications can improve detection in samples with heterogeneous phosphorylation patterns .

• Specialized imaging techniques: Implement super-resolution microscopy or other advanced imaging methods to improve spatial resolution and detection sensitivity for immunofluorescence applications.

How can researchers effectively compare and integrate data from different anti-pS2 antibodies?

Comparing and integrating data from different anti-pS2 antibodies requires careful consideration of their distinct binding characteristics:

• Differential binding profile analysis: Understand the distinct binding profiles of different antibodies. For example, E1Z3G preferentially binds to pSer2 in central positions, while EPR18855 and 2G1 have dramatically higher affinity (25-40 fold) for C-terminally positioned pSer2 . These differences must be factored into data interpretation.

• Normalization strategies: Develop appropriate normalization approaches when comparing data across different antibodies. Reference the binding to a common standard peptide (like peptide 35 or 37 mentioned in the studies) to calculate fold-change values relative to this standard .

• Complementary antibody approach: Use multiple antibodies with different binding characteristics to develop a more comprehensive understanding of the phosphorylation landscape. Cross-validate findings using antibodies from different sources that recognize the same epitope.

• Position-aware experimental design: When designing experiments to detect phosphorylation patterns, consider the positional preferences of different antibodies. Select the appropriate antibody based on whether the target phosphorylation site is likely to be in an N-terminal, central, or C-terminal position .

• Integrated data analysis framework: Develop computational approaches that integrate data from multiple antibodies, accounting for their known binding preferences and limitations. This can provide a more accurate representation of the actual phosphorylation state.

What are common sources of false positive and false negative results when using PS2 antibodies?

Several factors can contribute to false positive and false negative results when using PS2 antibodies:

Sources of false positives:

• Cross-reactivity with similar epitopes: Some anti-pS2 antibodies may recognize similar phosphorylated motifs in proteins other than the intended target.

• Bystander phosphorylation enhancement: Certain phosphorylation patterns can enhance antibody binding. For example, phosphorylation of Thr4 within the C-terminal heptad increased binding of EPR18855 and 2G1 antibodies, potentially leading to overestimation of pSer2 levels .

• Non-specific binding: Insufficient blocking or inappropriate antibody concentrations can increase background signal and lead to false positive interpretations.

• Phosphorylation-mimicking artifacts: Acidic amino acids or chemical modifications during sample preparation might mimic phosphorylation and be erroneously recognized by the antibody.

Sources of false negatives:

• Blocking effect of neighboring phosphorylations: Specific phosphorylation patterns can block antibody recognition. For instance, phosphorylation at Thr4 in the +2 position and Ser5 in the +3 position relative to pSer2 prevents recognition by anti-pS2 antibodies .

• Insufficient epitope exposure: Inadequate antigen retrieval in fixed tissues or incomplete protein denaturation can mask the epitope and prevent antibody binding.

• Contextual limitations: The antibody may not recognize the phosphorylated epitope when it occurs in certain structural or sequence contexts, such as when embedded within protein complexes.

• Epitope masking by protein interactions: Protein-protein interactions may physically block access to the phosphorylated site, preventing antibody binding despite the presence of the modification.

How can researchers address inconsistent results across different experimental platforms when using PS2 antibodies?

Addressing inconsistencies across platforms requires systematic troubleshooting and standardization:

• Platform-specific optimization: Recognize that optimal antibody concentrations and conditions differ across techniques. For instance, PS2 antibody concentrations range from 0.5-1 μg/ml for immunocytochemistry to 1:100-1:2000 dilutions for Western blot . Platform-specific optimization is essential.

• Standardized sample preparation: Develop consistent sample preparation protocols across platforms to minimize variability in epitope presentation. Pay particular attention to fixation, extraction, and denaturation methods.

• Internal controls and calibration standards: Include consistent internal controls and calibration standards across all platforms to enable normalization and direct comparison of results.

• Antibody validation across platforms: Validate each antibody specifically for each experimental platform rather than assuming transferability of validation from one method to another.

• Consideration of epitope accessibility differences: Recognize that epitope accessibility varies fundamentally between techniques (e.g., denatured proteins in Western blot versus partially preserved structures in immunohistochemistry). This may explain certain cross-platform inconsistencies.

• Multiple antibody approach: Use multiple antibodies recognizing different epitopes or the same epitope through different binding mechanisms to cross-validate findings across platforms.

• Complementary detection methods: Supplement antibody-based detection with non-antibody methods (such as mass spectrometry) to confirm results when discrepancies arise.

What are the critical considerations when interpreting PS2 antibody data in the context of phosphorylation dynamics?

Interpreting PS2 antibody data in the context of phosphorylation dynamics requires consideration of several complex factors:

• Temporal dynamics of phosphorylation: Recognize that phosphorylation states are dynamic and may change rapidly. Experimental design should account for appropriate time points to capture relevant phosphorylation events.

• Heterogeneity in phosphorylation patterns: Biological samples typically contain a mixture of different phosphorylation states. Anti-pS2 antibody signals represent an aggregate of this heterogeneity rather than a uniform state.

• Quantitative limitations: Antibody binding is not always linearly related to the amount of phosphorylation present. Factors such as epitope accessibility, antibody saturation, and the influence of neighboring modifications affect the quantitative interpretation of signal intensity.

• Context-dependent recognition: Interpreting antibody signals requires understanding the context-dependent nature of recognition. The binding of anti-pS2 antibodies is affected by:

  • Position of the phosphorylation within the peptide (N-terminal, central, or C-terminal)

  • Presence of additional phosphorylations nearby

  • Structural context of the epitope

• Differential antibody characteristics: Different anti-pS2 antibodies have distinct binding preferences. For example, E1Z3G prefers centrally positioned pSer2, while EPR18855 and 2G1 strongly prefer C-terminal pSer2 . These differences must be considered when comparing results across studies using different antibodies.

• Hierarchical effects of multiple phosphorylations: When interpreting data from complex phosphorylation patterns, consider the hierarchical nature of their effects. Some phosphorylations have dominant effects that override others – for example, the negative effect of phosphorylation at positions +2 and +3 relative to pSer2 overrides the positive effect of phosphorylation at position -2 .

How are synthetic peptide libraries advancing our understanding of PS2 antibody specificity?

Synthetic peptide libraries have revolutionized our understanding of PS2 antibody specificity through several innovative approaches:

• Development of native chemical ligation strategies: Advanced synthesis strategies now provide access to multiphosphorylated CTD peptides in high purity without HPLC purification. These techniques have enabled the assembly of 12 heptad repeats in various phosphoforms, allowing for unprecedented detailed analysis of antibody binding characteristics .

• Comprehensive positional scanning: The synthesis of over 60 CTD peptides (48-90 amino acids in length containing up to 6 phosphosites) has enabled systematic mapping of position-dependent epitope recognition. This has revealed that antibodies like E1Z3G prefer centrally positioned phosphorylation sites, while EPR18855 and 2G1 strongly favor C-terminal pSer2 positions .

• Multivalency analysis through peptide design: Synthetic libraries have allowed researchers to systematically test the hypothesis that multivalent binding enhances antibody affinity. Contrary to expectations, presenting multiple pSer2 residues at distances of 1-5 heptads enhanced affinity only minimally (<2-fold), likely due to the high flexibility of the CTD scaffold .

• Mapping of "bystander phosphorylation" effects: Synthetic peptide libraries have revealed complex interactions between neighboring phosphorylation sites. These studies demonstrated that phosphorylation of nearby residues can either block or enhance anti-pS2 antibody binding in a position-specific manner .

• Competition assay development: Synthetic peptides have enabled the development of sophisticated competition assays to precisely characterize antibody specificity. These assays confirmed that antibodies like E1Z3G, EPR18855, and 2G1 are highly specific for pSer2, as unphosphorylated peptides or peptides phosphorylated at other residues (pThr4, pSer5, or pSer7) failed to compete for antibody binding .

What emerging research areas could benefit from improved PS2 antibody applications?

Several emerging research areas stand to benefit significantly from advances in PS2 antibody applications:

• Single-cell phosphoproteomics: Improved PS2 antibodies with enhanced specificity and sensitivity could enable more accurate mapping of phosphorylation patterns at the single-cell level, providing insights into cellular heterogeneity in transcriptional regulation.

• Spatial transcriptomics integration: Combining PS2 antibody-based detection of RNA polymerase II phosphorylation states with spatial transcriptomics techniques could reveal location-specific transcriptional regulation mechanisms within tissues and cellular microenvironments.

• Dynamic phosphorylation landscape analysis: Development of PS2 antibodies with rapid binding kinetics and minimal epitope occupancy times could enable real-time monitoring of phosphorylation dynamics during transcriptional processes.

• Therapeutic targeting of phosphorylation-dependent interactions: Detailed understanding of phosphorylation recognition by PS2 antibodies could inform the development of therapeutic agents targeting phosphorylation-dependent protein-protein interactions in diseases with dysregulated transcription.

• Diagnostic applications in precision medicine: Highly specific PS2 antibodies could serve as diagnostic tools to detect altered phosphorylation patterns associated with disease states, potentially enabling earlier or more precise diagnosis of conditions involving transcriptional dysregulation.

• Multiplexed phosphorylation code analysis: Advanced multiplexing techniques using panels of phospho-specific antibodies, including PS2 antibodies, could enable comprehensive decoding of the phosphorylation patterns that regulate transcription in different cellular contexts.

How can researchers account for the contextual flexibility of the CTD in phosphorylation studies using PS2 antibodies?

The high flexibility of the CTD scaffold presents unique challenges for phosphorylation studies using PS2 antibodies. Researchers can address these challenges through several approaches:

• Length-appropriate peptide design: Studies have demonstrated that peptide length significantly affects antibody binding characteristics. Using peptides with 6-12 heptad repeats, rather than shorter fragments, provides a more physiologically relevant context for studying antibody recognition .

• Modeling structural ensembles: Rather than assuming a single conformation, researchers should conceptualize the CTD as an ensemble of rapidly interconverting structures. Computational approaches that model this conformational ensemble can provide insights into the accessibility of phosphorylation sites to antibodies.

• In-solution binding studies: Complement solid-phase binding assays with in-solution techniques that allow the CTD to maintain its natural flexibility during antibody binding. Techniques such as fluorescence polarization or isothermal titration calorimetry can provide complementary insights.

• Consideration of multivalency limitations: Research has shown that the high flexibility of the CTD scaffold limits multivalency-enhanced binding . Experimental designs should account for this limitation and not assume significant avidity effects even when multiple epitopes are present.

• Dynamic phosphorylation analysis: Develop experimental approaches that capture the dynamic nature of phosphorylation and CTD conformation, such as time-resolved studies following stimulation or stress.

• Context-specific validation: Validate antibody binding characteristics in the specific experimental context rather than relying solely on synthetic peptide data. The complex cellular environment may influence CTD conformation and subsequent antibody recognition in ways not predicted by in vitro studies.

• Integration with structural techniques: Combine antibody-based detection with structural techniques like NMR or small-angle X-ray scattering that can provide insights into the ensemble of conformations adopted by the phosphorylated CTD in different contexts.